Bristol Myers CEO sees mid-decade transition, late decade growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales
February 2, 2024 7:42 AM ESTShares of Bristol-Myers Squibb (NYSE: BMY) advanced 2.5% in the market pre-open Friday after the pharmaceutical company unveiled better-than-expected earnings and revenue for the fiscal fourth quarter.
Notably, Bristol reported Q4 earnings per share (EPS) of $1.70, ahead of Wall Streets consensus of $1.60. Revenue stood at $11.48 billion in the... More
